RxDoctor Payments DataLook up a doctor →

William Simon, DO

Family Medicine · Wichita, KSNPI 1952352007

Payments from drug & device makers

$1,119,978in general payments, 2019–2025

Across 1,120 payments — averaging $999.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$776K
  • Amgen$128K
  • Regeneron$79K
  • Sanofi US Services Inc.$74K
  • Pfizer$26K
  • Lexicon Pharmaceuticals, Inc.$19K
  • plus $18K from 54 others

What the payments were for

  • Food & beverage$14,104100%
  • Education$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK279$775,745
Amgen(2 entities)65$127,587
Regeneron38$79,157
Sanofi US Services Inc.25$73,731
Pfizer52$26,188
Lexicon Pharmaceuticals, Inc.1$19,383
Novo Nordisk AS2$6,220
Novo Nordisk122$3,148
AbbVie(2 entities)134$1,821
AstraZeneca52$1,436
Lilly USA, LLC88$1,051
Astellas Pharma US Inc29$486
Amarin Pharma, Inc.33$433
Abbott11$302
Vanda Pharmaceuticals Inc.6$235
Jazz Pharmaceuticals Inc.10$231
Bayer13$216
Sanofi Pasteur Inc.9$185
Idorsia Pharmaceuticals US Inc8$184
Merck13$184
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$175
Biohaven Pharmaceuticals, Inc.10$157
Johnson & Johnson7$146
Sunovion Pharmaceuticals Inc.11$107
Sanofi-aventis U.S. LLC7$106
Corcept Therapeutics6$106
Teva Pharmaceuticals USA, Inc.6$100
Takeda Pharmaceuticals U.S.A., Inc.6$88
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$78
Cranial Technologies, Inc4$74
Esperion Therapeutics, Inc.4$67
Regeneron Healthcare Solutions, Inc.3$64
Currax Pharmaceuticals LLC3$62
Phathom Pharmaceuticals, Inc.3$56
Biohaven Pharmaceutical Holding Company Ltd.4$55
Upsher-smith Laboratories LLC3$51
Exact Sciences3$45
Eisai Inc.2$39
Mylan Specialty L.p.3$37
IBSA Pharma Inc.1$28
Arbor Pharmaceuticals, Inc.2$28
Medtronic1$27
Neos Therapeutics, LP2$24
Boehringer Ingelheim2$24
Alnylam Pharmaceuticals Inc.1$24
Adlon Therapeutics L.p.2$24
Dexcom, Inc.1$24
Tactile Systems Technology Inc1$22
Antares Pharma, Inc.1$18
Amneal Pharmaceuticals LLC1$17
Otsuka America Pharmaceutical, Inc.1$17
Sobi, Inc1$16
Corium, LLC1$16
Shire North American Group Inc1$16
Nalpropion Pharmaceuticals LLC1$16
Lundbeck LLC1$14
Kowa Pharmaceuticals America, Inc.1$14
Xeris Pharmaceuticals, Inc.1$14
Strongbridge US Inc.1$13
Acelrx Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,119,978 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$75,676
Medicare patients
264
Services billed
14,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$34,323
XareltoRivaroxaban19$15,847
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$14,785
EliquisApixaban20$12,227
OzempicSemaglutide13$11,097
Tresiba Flextouch U-200Insulin Degludec16$9,379
Janumet XrSitagliptin Phos/Metformin Hcl14$9,095
TrulancePlecanatide14$7,838
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,693
VascepaIcosapent Ethyl15$5,867
MyrbetriqMirabegron12$5,729
Esomeprazole Magnesium15$3,175
Donepezil Hcl73$2,848
Levothyroxine Sodium241$1,873
Potassium Chloride101$1,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,051$34,32331 claims
Johnson & JohnsonXarelto$146$15,84719 claims
AstraZenecaBreztri Aerosphere$1,436$14,78522 claims
PfizerEliquis$26,188$12,22720 claims
Novo NordiskOzempic$3,148$11,09713 claims
MerckJanumet Xr$184$9,09514 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$175$7,83814 claims
GSKTrelegy Ellipta$775,745$7,69312 claims
Astellas Pharma US IncMyrbetriq$486$5,72912 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$1,873241 claims
AbbVieSynthroid$1,821$1,51825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →